Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 19/20 | 1.00 |
| ▸ | LPAR2 | Q9HBW0 | 15/20 | 1.00 |
| ▸ | LPAR1 | Q92633 | 13/20 | 0.78 |
| ▸ | LPAR6 | P43657 | 4/20 | 0.59 |
| ▸ | LPAR4 | Q99677 | 4/20 | 0.59 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1974389 | 1.00 | LPAR3 (1.00) | LPAR3LPAR2LPAR1LPAR6LPAR4 | |
| SCHEMBL258195 | 1.00 | LPAR3 (1.00) | LPAR3LPAR2LPAR1LPAR6LPAR4 | |
| SCHEMBL40320 | 1.00 | LPAR3 (1.00) | LPAR3LPAR2LPAR1LPAR6LPAR4 | |
| Thiophosphoric Acid Tetradecyl Ester SCHEMBL193777 | 1.00 | LPAR3 (1.00) | LPAR3LPAR2LPAR1LPAR6LPAR4 | |
| SCHEMBL8657418 | 1.00 | LPAR3 (1.00) | LPAR3LPAR2LPAR1LPAR6LPAR4 | |
| Thiophosphoric Acid Dodecyl Ester SCHEMBL40052 | 1.00 | LPAR3 (1.00) | LPAR3LPAR2LPAR1LPAR6LPAR4 | |
| SCHEMBL8469365 | 1.00 | LPAR3 (1.00) | LPAR3LPAR2LPAR1LPAR6LPAR4 | |
| SCHEMBL8372319 | 1.00 | LPAR3 (1.00) | LPAR3LPAR2LPAR1LPAR6LPAR4 | |
| SCHEMBL6695704 | 1.00 | LPAR3 (1.00) | LPAR3LPAR2LPAR1LPAR6LPAR4 | |
| SCHEMBL31749062 | 1.00 | LPAR3 (1.00) | LPAR3LPAR2LPAR1LPAR6LPAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2481743-B1 | LPA receptor agonists and antagonists and methods of use | UNIV TENNESSEE RES FOUND (US) | 2017-03-22 | — | — | EP | claimed |
| EP-2433946-B1 | LPA receptor agonists and antagonists and methods of use | UNIV TENNESSEE RES FOUNDATION (US) | 2016-04-20 | — | — | EP | claimed |
| EP-2481743-A1 | LPA receptor agonists and antagonists and methods of use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2012-08-01 | — | — | EP | claimed |
| EP-2433946-A1 | LPA receptor agonists and antagonists and methods of use | University of Tennessee Research Foundation (US) | 2012-03-28 | — | — | EP | claimed |
| EP-1906972-A2 | LPA2 RECEPTOR AGONIST INHIBITORS OF CFTR | The University of Tennessee Research Foundation (US) | 2008-04-09 | — | — | EP | claimed |
| EP-1678096-A4 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES CORP (US) | 2007-04-18 | — | — | EP | claimed |
| US-20070078111-A1 | LPA2 receptor agonist inhibitors of CFTR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-04-05 | — | — | US | claimed |
| JP-2007508324-A | — | — | 2007-04-05 | — | — | JP | claimed |
| WO-2007011905-A2 | LPA2 RECEPTOR AGONIST INHIBITORS OF CFTR | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-01-25 | — | — | WO | claimed |
| EP-1678096-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2006-07-12 | — | — | EP | claimed |
| US-20060009507-A1 | Thio-phosphoric and -phosphorous acid derivatives; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-01-12 | — | — | US | claimed |
| WO-2005032494-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-04-14 | — | — | WO | claimed |
| US-10336859-B2 | Method for preparing an electrolyte capacitor | TAYCA CORPORATION (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20190106531-A1 | Method for preparing an electrolyte capacitor | TAYCA CORPORATION (JP) | 2019-04-11 | — | — | US | disclosed |
| US-10208160-B2 | Oxidant dopant agent for conductive polymer production, and a solution thereof, and a conductive polymer prepared by using either of them, as well as an electrolyte capacitor using the conductive polymer as an electrolyte | TAYCA CORPORATION (JP) | 2019-02-19 | — | — | US | disclosed |
| EP-2481743-B1 | LPA receptor agonists and antagonists and methods of use | UNIV TENNESSEE RES FOUND (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-0459656-A1 | Lubricant compositions | ETHYL PETROLEUM ADDITIVES, INC. (US) | 1991-12-04 | — | — | EP | disclosed |
| EP-0013744-B1 | CATALYST AND PROCESS FOR THE POLYMERIZATION OF ALPHA-OLEFINS AND A PROCESS FOR PREPARING AN ALPHA-OLEFIN POLYMERIZATION CATALYST COMPONENT | Standard Oil Company (US) | 1984-11-07 | — | — | EP | disclosed |
| US-4233182-A | High activity catalyst for the polymerization of alpha-olefins | STANDARD OIL COMPANY (INDIANA) (US) | 1980-11-11 | — | — | US | disclosed |
| EP-0013744-A1 | Catalyst and process for the polymerization of alpha-olefins and a process for preparing an alpha-olefin polymerization catalyst component | Standard Oil Company (US) | 1980-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009507-A1 | Thio-phosphoric and -phosphorous acid derivatives; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | LPAR1, LPAR6, LPAR2 | LPAR3 6/4885LPAR2 3/4885LPAR1 1/4885 |
| US-20070078111-A1 | LPA2 receptor agonist inhibitors of CFTR | LPAR2, NHERF1, LPAR1 | LPAR3 6/4885LPAR2 1/4885LPAR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.